On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
A Pipeline Built On Precision
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency’s Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz’s existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company’s highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
The Price Of Ambition
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company’s liquid resources.
Jazz’s recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in metastatic small cell lung cancer, following results from the LAGOON trial, trimming one use even as others expand.
Funds Trim As Skeptics Circle
Hedge fund ownership of Jazz slipped from 48 funds to 46 in the most recent quarter, a modest pullback rather than a rush for the exits. Short interest sits at 7.33% of the float, a level that points to a real bear camp watching the stock rather than casual skepticism. Against that, shares trade at a forward price-to-earnings ratio of just 11.03 as of September 17, a multiple that assumes little of the growth management is currently guiding toward. That gap between a cautious market and an accelerating business is the tension running through the stock right now.
What Comes Next For Jazz
Jazz now has a rare disease pipeline broadened by a potential first-in-class epilepsy drug, a record quarter behind it, and a diversifying oncology business ahead of it. It also carries more committed cash against an asset that remains years from approval, plus a track record of acquisition charges that can rattle GAAP earnings along the way. ABS-1230’s path through further trials and zanidatamab’s ongoing regulatory progress will likely decide whether this quarter’s growth number was a peak or a new baseline.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
